CureVac soars on COVID, influenza vaccines deal with GSK

CureVac NV

03/07/2024 08:55

** Frankfurt-listed shares in CureVac  5CV.DE  jump around
24% after British drugmaker GSK  GSK.L  said it will take
control of several vaccines the two companies were jointly
developing
    ** GSK said it will pay CureVac 400 million euros ($430.12
million) upfront and up to an additional 1.05 billion euros, in
development, regulatory and sales milestones as well as tiered
royalties
    ** CureVac said it will focus its resources on high-value
mRNA projects and cut its workforce by about 30%
    ** If gains hold, CureVac's stock will see its best day
since January 2023
 


($1 = 0.9300 euros)

 (Reporting by Tristan Veyet)
 ((Tristan.chabba@thomsonreuters.com))